Aid organisation Médecins Sans Frontières is
demanding that drug companies cut the cost of pneumonia vaccines for poor
children worldwide, a move that could greatly affect Myanmar.
MSF has
presented a petition with nearly 400,000 signatures to pharmaceutical giants
Pfizer and GlaxoSmithKline asking that they drop the vaccine cost to US$5 per
child in all developing countries and for humanitarian organisations.
Pneumonia
is the leading cause of vaccine-preventable deaths in Myanmar. Recent UNICEF
data shows pneumonia accounted for 16 percent of under-five deaths in 2015,
with 7516 losing their lives because of the disease.
Myanmar
is due to introduce a new pneumococcal vaccine for pneumonia in the coming
months. The $20 million project, co-financed by the government and the Global
Alliance for Vaccines and Immunisation (GAVI), is slated to run from 2016 to
2020.
A
spokesperson for GAVI said they will be purchasing these vaccines from GSK,
with each course costing around $9. But if MSF’s cost-slashing request is
successful, savings could amount to around $10 million.
Dr Greg
Elder, medical coordinator at MSF’s Access Campaign said, “After combined sales
of more than $30 billion for the pneumonia vaccine alone, we think it’s pretty
safe to say that Pfizer and GSK can afford to lower the price.”
Dr Andrea
Incerti of MSF Myanmar said that the pneumonia vaccine, even at the lowest
global price, is still “much more expensive” than almost any other vaccine.
“There
are many tragedies that cost children’s lives that we can’t do anything about,
but today no child should be dying of a vaccine preventable disease like
pneumonia,” Dr Incerti said.
Lowering
vaccine costs is a move supported by multiple health actors that operate in
Myanmar including many NGOs and United Nations agencies.
“Lowering
vaccine costs is crucial to increase access … [It] will enable the most
marginalised and vulnerable children to be protected from vaccine-preventable
diseases, thus reducing deaths among children under-five,” said Maharajan
Muthu, Maternal and Child Health Specialist at UNICEF Myanmar.
But drug
companies disagree with the suggested ease of lowering the fee. In a statement,
drug company GSK said at current production “we are able to just cover our
costs and maintain our ability to supply the vaccine to these countries in the
long-term”.
The
organisation said it was committed to “looking at ways to reduce production
costs”.
MSF
estimates that pneumonia kills almost 1 million children around the world
annually.
Last
year, 193 governments at the World Health Assembly unanimously passed a resolution
demanding more affordable vaccines and increased transparency around vaccine
prices.
Several
countries indicated at the event that they are not able to introduce the
pneumonia vaccine because of its high price.
By Nick
Baker
No comments:
Post a Comment